Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

NCT02157935 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2026

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD Patients

Interventions

DRUG: Symbicort
DRUG: Formoterol turbohaler
OTHER: Placebo for Symbicort pMDI
OTHER: Placebo for Formoterol Turbohaler

Sponsor

AstraZeneca